Treat it now or watch it: a four feature rule for a new keloid

A scar that should have flattened is instead thickening, and the person it belongs to is doing what almost everyone does at this stage, which is nothing. Not out of neglect. Out of a completely reasonable belief that scars settle with time, that this one might too, and that seeing a dermatologist about a scar feels like an overreaction.

Sometimes that belief is correct. Sometimes the thing that is thickening is a hypertrophic scar, which stays inside the original wound boundary and does frequently improve on its own over a year or two. And sometimes it is a keloid, which does not, and every month of waiting adds volume that later has to be treated, at a rate that is not linear.

The original element in this piece is a four feature decision rule for whether a new raised scar should be treated now or watched, using age of the scar, growth trajectory, symptom load and anatomical site, with a statement of what each answer changes and an explicit account of what the evidence cannot tell you about waiting. Patient guidance on keloids describes what they are and lists the treatments. It does not address the question that actually confronts someone at month four, which is whether this is the moment.

Feature one, the age of the scar and what it is doing. A wound that closed six weeks ago and is red, raised and firm is not yet diagnostic of anything. Normal healing includes a proliferative phase where scars are elevated and pink, and a good proportion of them then remodel and flatten. The question is not whether it is raised at week six. It is whether it is still growing at month three. A scar that is stable in size at three months, even if raised, is behaving like a hypertrophic scar. A scar that is measurably larger at month three than at month two, and larger again at month four, is not remodeling, and that trajectory is the strongest single signal in this whole assessment.

Feature two, the boundary. This is the distinction that carries most of the diagnostic weight and it is the one people can check themselves. A hypertrophic scar stays within the footprint of the original injury. A keloid grows past it, extending into skin that was never wounded, often with a lobed or clawed edge that reaches into normal tissue. Find the original wound line, which is usually still visible as a paler central band, and ask whether the raised tissue extends beyond where the cut or the piercing or the acne lesion actually was. If it does, you are dealing with the keloid rather than the hypertrophic pattern, and the natural history is entirely different.

Feature three, symptom load. Itch and pain are treated in most conversations as a comfort issue and a secondary one. They should not be. Work on the burden of keloid disease found that quality of life impact tracks poorly with size, which cuts both ways: a large quiet scar may be tolerable, and a small one that itches constantly or hurts when a seatbelt crosses it is a genuine clinical problem that deserves treatment independent of how it looks. If you are scratching it, if it wakes you, if you have changed what you wear because of it, that is a treat now feature and it does not need to be justified by size.

Feature four, site. Some locations are simply worse actors. The presternal chest, the shoulders and upper back, the jawline, and the earlobe are the classic high tension or high recurrence zones. A raised scar on the front of the chest that is growing is the combination least likely to resolve on its own and the one where the case for early intervention is strongest. A small firm scar on the lower leg or the abdomen has more room for a watchful approach.

Reading the four together. Boundary crossed, still growing at three months, symptomatic, high risk site: that is four for four and the answer is that this is a treat now scar, and the treatment that gets started is usually intralesional steroid, the workhorse of the field, sometimes with an added agent. Boundary respected, stable at three months, no symptoms, low risk site: that is a watch, with a photograph and a ruler once a month and a review at six months. Anything in between, and particularly any scar that is growing regardless of the other three, tips toward being seen, because growth is the feature that changes what treatment will be needed later.

Why waiting is not neutral. Long term series following keloids through treatment protocols, including work on recurrence free intervals after standardized protocols, consistently show that these are lesions where the treatment burden scales with the lesion. A small keloid may be controlled with a short series of injections. A large one frequently ends up requiring combination approaches, which means more sessions, more cost, and in some cases surgery with adjuvant therapy afterward. That is the real currency of the decision. Waiting does not usually cost you the possibility of a good outcome. It costs you sessions, and it costs you money, which is worth knowing before the price of a course of treatment becomes a surprise.

What is genuinely fine to wait on. A scar that is flat and merely discolored. A raised scar at week six with no history of keloids anywhere else on your body, in a low risk site, that has not yet had three months to show what it will do. A scar you have been treating with silicone and pressure for less than three months, since those measures are slow and judging them at week four is judging them too early. The general treatment framework used by dermatology bodies including the American Academy of Dermatology reflects the same staging: conservative measures first in the right candidates, escalation when the scar declares itself.

What the studies do not tell you. There is no published trial comparing early treatment with delayed treatment of keloids, and there is unlikely ever to be one, because randomizing people to wait with a growing lesion is not a study anybody will run. Everything above about the cost of waiting is inferred from treatment series showing that larger and older lesions need more, and from the mechanism of continued collagen deposition, rather than from a direct comparison. The four feature rule is a synthesis, not a validated instrument, and it will occasionally send someone to a clinic who did not need to go. That is the direction in which the error is cheap.

The instruction that actually matters is narrower than it sounds. Photograph the scar this week with a ruler beside it, do it again in four weeks, and if it is bigger, stop watching.